A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
Completed · Phase 1 · NCT06440980
Conditions: Healthy, Obese, Overweight, Obesity
At a glance
- Research payments reported, 2025
- $79.8M
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 533
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Orforglipron (drug)
- Dates
- Started 2024-06-24; completion 2025-06-02
- Results posted
- Yes
The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated. The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period.
From ClinicalTrials.gov, last updated 2026-07-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $79.8M in research payments for this study in 2025 (8 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Amina Z. Haggag, M.D. Family Medicine · Northridge, CA
- Steven H. Reynolds, D.O. Family Medicine · Long Beach, CA
- Hugh A. Coleman, DO Family Medicine · Daytona Beach, FL
- Martin K. Kankam, MD Internal Medicine · Leavenworth, KS
- Kathleen M. Doisy, MD Pediatrics · Columbia, MO
- William J. Howitt, MD Family Medicine · Springfield, MO
- Archie V. Bowie II, MD Student in an Organized Health Care Education/Training Program · Odessa, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research Unit Inc $21.7M
- Fortrea Clinical Research Unit Inc $16.8M
- Covance Clinical Research LP Dallas $11.9M
- Bio Kinetic Clinical Applications LLC $10.7M
- Anaheim Clinical Trials LLC $7.6M
- Collaborative Neuroscience Research LLC $6.4M
- Altasciences Clinical Kansas P A $4.9M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.